logo
  

Cochlear To Immediately Begin Controlled Market Release Of Remote Assist In The U.S.

Cochlear Limited has received FDA approval in September for the company's Cochlear Remote Assist solution in the Nucleus and Baha Systems. Cochlear noted that the FDA approval for the implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022.

Cochlear said it will immediately begin a controlled market release of Remote Assist in the U.S. by partnering with hearing healthcare providers and hospitals.

The company expects Remote Assist approval in Canada in late 2021 for the Nucleus System and early 2022 for the Baha System.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula. Shares of Deutsche Telekom AG were gaining more than 1 percent in the morning trading in Germany after the telecom major on Thursday raised its fiscal 2022 earnings outlook again, despite reporting lower profit in its second quarter. Adjusted EBITDA AL, a key earnings metric, increased, while adjusted EBITDA AL margin dropped.
Follow RTT